Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 145 entries
Sorted by: Best Match Show Resources per page
A new concept of automated radiochemical analysis based on substoichiometric separation.

Talanta

Ruzicka J, Lamm CG.
PMID: 18960350
Talanta. 1968 Jul;15(7):689-97. doi: 10.1016/0039-9140(68)80153-5.

Tracer methods, such as radioisotope dilution, radiometric analysis, concentration dependent distribution, saturation analysis etc., are compared on a basis of radioactivity-mass balance relationships, and their automation is proposed. The requirements of a chemical separation, which is an integral part...

Cite
Ruzicka J, Lamm CG. A new concept of automated radiochemical analysis based on substoichiometric separation. Talanta. 1968;15(7):689-97doi: 10.1016/0039-9140(68)80153-5.
Ruzicka, J., & Lamm, C. G. (1968). A new concept of automated radiochemical analysis based on substoichiometric separation. Talanta, 15(7), 689-97. https://doi.org/10.1016/0039-9140(68)80153-5
Ruzicka, J, and Lamm, C G. "A new concept of automated radiochemical analysis based on substoichiometric separation." Talanta vol. 15,7 (1968): 689-97. doi: https://doi.org/10.1016/0039-9140(68)80153-5
Ruzicka J, Lamm CG. A new concept of automated radiochemical analysis based on substoichiometric separation. Talanta. 1968 Jul;15(7):689-97. doi: 10.1016/0039-9140(68)80153-5. PMID: 18960350.
Copy Download .nbib Format: NLM
Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure.

Visceral medicine

Trebicka J, Reiberger T, Laleman W.
PMID: 30345284
Visc Med. 2018 Aug;34(4):270-275. doi: 10.1159/000490262. Epub 2018 Jul 13.

Acute-on-chronic liver failure (ACLF) is considered a distinct syndrome in patients with liver disease, with systemic inflammation playing a central role. Portal hypertension (PHT) is also aggravated by inflammation and may subsequently impact the course of ACLF. PHT is...

Cite
Trebicka J, Reiberger T, Laleman W. Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. Visc Med. 2018;34(4):270-275doi: 10.1159/000490262.
Trebicka, J., Reiberger, T., & Laleman, W. (2018). Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. Visceral medicine, 34(4), 270-275. https://doi.org/10.1159/000490262
Trebicka, Jonel, et al. "Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure." Visceral medicine vol. 34,4 (2018): 270-275. doi: https://doi.org/10.1159/000490262
Trebicka J, Reiberger T, Laleman W. Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. Visc Med. 2018 Aug;34(4):270-275. doi: 10.1159/000490262. Epub 2018 Jul 13. PMID: 30345284; PMCID: PMC6189544.
Copy Download .nbib Format: NLM
Acute-on-Chronic Liver Failure.

Visceral medicine

Lange CM, Bechstein WO, Berg T, Engelmann C, Bruns T, Canbay A, Moreau R, Trebicka J.
PMID: 30345288
Visc Med. 2018 Aug;34(4):296-300. doi: 10.1159/000491406. Epub 2018 Jul 12.

No abstract available.

Cite
Lange CM, Bechstein WO, Berg T, et al. Acute-on-Chronic Liver Failure. Visc Med. 2018;34(4):296-300doi: 10.1159/000491406.
Lange, C. M., Bechstein, W. O., Berg, T., Engelmann, C., Bruns, T., Canbay, A., Moreau, R., & Trebicka, J. (2018). Acute-on-Chronic Liver Failure. Visceral medicine, 34(4), 296-300. https://doi.org/10.1159/000491406
Lange, Christian M, et al. "Acute-on-Chronic Liver Failure." Visceral medicine vol. 34,4 (2018): 296-300. doi: https://doi.org/10.1159/000491406
Lange CM, Bechstein WO, Berg T, Engelmann C, Bruns T, Canbay A, Moreau R, Trebicka J. Acute-on-Chronic Liver Failure. Visc Med. 2018 Aug;34(4):296-300. doi: 10.1159/000491406. Epub 2018 Jul 12. PMID: 30345288; PMCID: PMC6189541.
Copy Download .nbib Format: NLM
[Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)].

Zeitschrift fur Gastroenterologie

Gerbes AL, Labenz J, Appenrodt B, Dollinger M, Gundling F, Gülberg V, Holstege A, Lynen-Jansen P, Steib CJ, Trebicka J, Wiest R, Zipprich A.
PMID: 31127596
Z Gastroenterol. 2019 May;57(5):e168. doi: 10.1055/a-0928-2800. Epub 2019 May 24.

No abstract available.

Cite
Gerbes AL, Labenz J, Appenrodt B, et al. Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“. [Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)]. Z Gastroenterol. 2019;57(5):e168doi: 10.1055/a-0928-2800.
Gerbes, A. L., Labenz, J., Appenrodt, B., Dollinger, M., Gundling, F., Gülberg, V., Holstege, A., Lynen-Jansen, P., Steib, C. J., Trebicka, J., Wiest, R., Zipprich, A. (2019). Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“. [Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)]. Zeitschrift fur Gastroenterologie, 57(5), e168. https://doi.org/10.1055/a-0928-2800
Gerbes, Alexander L, et al. "Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“." [Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)]. Zeitschrift fur Gastroenterologie vol. 57,5 (2019): e168. doi: https://doi.org/10.1055/a-0928-2800
Gerbes AL, Labenz J, Appenrodt B, Dollinger M, Gundling F, Gülberg V, Holstege A, Lynen-Jansen P, Steib CJ, Trebicka J, Wiest R, Zipprich A. Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“. [Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)]. Z Gastroenterol. 2019 May;57(5):e168. doi: 10.1055/a-0928-2800. Epub 2019 May 24. German. PMID: 31127596.
Copy Download .nbib Format: NLM
Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction.

Frontiers in physiology

Sauerbruch T, Hennenberg M, Trebicka J, Beuers U.
PMID: 34393832
Front Physiol. 2021 Jul 29;12:718783. doi: 10.3389/fphys.2021.718783. eCollection 2021.

The bile acid pool with its individual bile acids (BA) is modulated in the enterohepatic circulation by the liver as the primary site of synthesis, the motility of the gallbladder and of the intestinal tract, as well as by...

Cite
Sauerbruch T, Hennenberg M, Trebicka J, et al. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol. 2021;12:718783doi: 10.3389/fphys.2021.718783.
Sauerbruch, T., Hennenberg, M., Trebicka, J., & Beuers, U. (2021). Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Frontiers in physiology, 12718783. https://doi.org/10.3389/fphys.2021.718783
Sauerbruch, Tilman, et al. "Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction." Frontiers in physiology vol. 12 (2021): 718783. doi: https://doi.org/10.3389/fphys.2021.718783
Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol. 2021 Jul 29;12:718783. doi: 10.3389/fphys.2021.718783. eCollection 2021. PMID: 34393832; PMCID: PMC8358446.
Copy Download .nbib Format: NLM
Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018).

The Lancet regional health. Europe

Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, Ferstl P, Schulz M, Peiffer KH, Queck A, Sauerbruch T, Brol MJ, Rohde G, Sanchez C, Moreau R, Arroyo V, Zeuzem S, Welsch C, Trebicka J.
PMID: 34901909
Lancet Reg Health Eur. 2021 Nov 04;12:100240. doi: 10.1016/j.lanepe.2021.100240. eCollection 2022 Jan.

BACKGROUND: Cirrhosis is known to have a high prevalence and mortality worldwide. However, in Europe, the epidemiology of cirrhosis is possibly undergoing demographic changes, and etiologies may have changed due to improvements in standard of care. The aim of...

Cite
Gu W, Hortlik H, Erasmus HP, et al. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur. 2021;12:100240doi: 10.1016/j.lanepe.2021.100240.
Gu, W., Hortlik, H., Erasmus, H. P., Schaaf, L., Zeleke, Y., Uschner, F. E., Ferstl, P., Schulz, M., Peiffer, K. H., Queck, A., Sauerbruch, T., Brol, M. J., Rohde, G., Sanchez, C., Moreau, R., Arroyo, V., Zeuzem, S., Welsch, C., & Trebicka, J. (2022). Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). The Lancet regional health. Europe, 12100240. https://doi.org/10.1016/j.lanepe.2021.100240
Gu, Wenyi, et al. "Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018)." The Lancet regional health. Europe vol. 12 (2022): 100240. doi: https://doi.org/10.1016/j.lanepe.2021.100240
Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, Ferstl P, Schulz M, Peiffer KH, Queck A, Sauerbruch T, Brol MJ, Rohde G, Sanchez C, Moreau R, Arroyo V, Zeuzem S, Welsch C, Trebicka J. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur. 2021 Nov 04;12:100240. doi: 10.1016/j.lanepe.2021.100240. eCollection 2022 Jan. PMID: 34901909; PMCID: PMC8640738.
Copy Download .nbib Format: NLM
Targeting the cytoplasmic polyadenylation element-binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis.

Molecular metabolism

Pell N, Garcia-Pras E, Gallego J, Naranjo-Suarez S, Balvey A, Suñer C, Fernandez-Alfara M, Chanes V, Carbo J, Ramirez-Pedraza M, Reina O, Thingholm L, Bang C, Rühlemann M, Franke A, Schierwagen R, Rheinwalt KP, Trebicka J, Mendez R, Fernandez M.
PMID: 34774811
Mol Metab. 2021 Dec;54:101388. doi: 10.1016/j.molmet.2021.101388. Epub 2021 Nov 10.

OBJECTIVE: Obesity represents a growing health problem that is reaching pandemic dimensions and lacks effective cures, thus highlighting an urgent need for better mechanistic understanding and new therapeutic strategies. Unlike transcription, the function of translation in obesity has hardly...

Cite
Pell N, Garcia-Pras E, Gallego J, et al. Targeting the cytoplasmic polyadenylation element-binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis. Mol Metab. 2021;54:101388doi: 10.1016/j.molmet.2021.101388.
Pell, N., Garcia-Pras, E., Gallego, J., Naranjo-Suarez, S., Balvey, A., Suñer, C., Fernandez-Alfara, M., Chanes, V., Carbo, J., Ramirez-Pedraza, M., Reina, O., Thingholm, L., Bang, C., Rühlemann, M., Franke, A., Schierwagen, R., Rheinwalt, K. P., Trebicka, J., Mendez, R., & Fernandez, M. (2021). Targeting the cytoplasmic polyadenylation element-binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis. Molecular metabolism, 54101388. https://doi.org/10.1016/j.molmet.2021.101388
Pell, Nuria, et al. "Targeting the cytoplasmic polyadenylation element-binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis." Molecular metabolism vol. 54 (2021): 101388. doi: https://doi.org/10.1016/j.molmet.2021.101388
Pell N, Garcia-Pras E, Gallego J, Naranjo-Suarez S, Balvey A, Suñer C, Fernandez-Alfara M, Chanes V, Carbo J, Ramirez-Pedraza M, Reina O, Thingholm L, Bang C, Rühlemann M, Franke A, Schierwagen R, Rheinwalt KP, Trebicka J, Mendez R, Fernandez M. Targeting the cytoplasmic polyadenylation element-binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis. Mol Metab. 2021 Dec;54:101388. doi: 10.1016/j.molmet.2021.101388. Epub 2021 Nov 10. PMID: 34774811; PMCID: PMC8711066.
Copy Download .nbib Format: NLM
Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates.

Frontiers in microbiology

Schultze TG, Ferstl PG, Villinger D, Hogardt M, Bechstein WO, Göttig S, Wichelhaus TA, Zeuzem S, Trebicka J, Waidmann O, Welker MW, Kempf VAJ.
PMID: 34880850
Front Microbiol. 2021 Nov 22;12:791574. doi: 10.3389/fmicb.2021.791574. eCollection 2021.

No abstract available.

Cite
Schultze TG, Ferstl PG, Villinger D, et al. Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates. Front Microbiol. 2021;12:791574doi: 10.3389/fmicb.2021.791574.
Schultze, T. G., Ferstl, P. G., Villinger, D., Hogardt, M., Bechstein, W. O., Göttig, S., Wichelhaus, T. A., Zeuzem, S., Trebicka, J., Waidmann, O., Welker, M. W., & Kempf, V. A. J. (2021). Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates. Frontiers in microbiology, 12791574. https://doi.org/10.3389/fmicb.2021.791574
Schultze, Tilman G, et al. "Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates." Frontiers in microbiology vol. 12 (2021): 791574. doi: https://doi.org/10.3389/fmicb.2021.791574
Schultze TG, Ferstl PG, Villinger D, Hogardt M, Bechstein WO, Göttig S, Wichelhaus TA, Zeuzem S, Trebicka J, Waidmann O, Welker MW, Kempf VAJ. Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates. Front Microbiol. 2021 Nov 22;12:791574. doi: 10.3389/fmicb.2021.791574. eCollection 2021. PMID: 34880850; PMCID: PMC8645865.
Copy Download .nbib Format: NLM
Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis.

JHEP reports : innovation in hepatology

Torp N, Israelsen M, Madsen B, Lutz P, Jansen C, Strassburg C, Mortensen C, Knudsen AW, Sorensen GL, Holmskov U, Schlosser A, Thiele M, Trebicka J, Krag A.
PMID: 34041469
JHEP Rep. 2021 Mar 29;3(3):100287. doi: 10.1016/j.jhepr.2021.100287. eCollection 2021 Jun.

BACKGROUND & AIMS: Prognostic models of cirrhosis underestimate disease severity for patients with cirrhosis and ascites. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein linked to hepatic neoangiogenesis and fibrogenesis. We investigated ascites MFAP4 as a predictor of...

Cite
Torp N, Israelsen M, Madsen B, et al. Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Rep. 2021;3(3):100287doi: 10.1016/j.jhepr.2021.100287.
Torp, N., Israelsen, M., Madsen, B., Lutz, P., Jansen, C., Strassburg, C., Mortensen, C., Knudsen, A. W., Sorensen, G. L., Holmskov, U., Schlosser, A., Thiele, M., Trebicka, J., & Krag, A. (2021). Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP reports : innovation in hepatology, 3(3), 100287. https://doi.org/10.1016/j.jhepr.2021.100287
Torp, Nikolaj, et al. "Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis." JHEP reports : innovation in hepatology vol. 3,3 (2021): 100287. doi: https://doi.org/10.1016/j.jhepr.2021.100287
Torp N, Israelsen M, Madsen B, Lutz P, Jansen C, Strassburg C, Mortensen C, Knudsen AW, Sorensen GL, Holmskov U, Schlosser A, Thiele M, Trebicka J, Krag A. Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Rep. 2021 Mar 29;3(3):100287. doi: 10.1016/j.jhepr.2021.100287. eCollection 2021 Jun. PMID: 34041469; PMCID: PMC8141937.
Copy Download .nbib Format: NLM
PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.

Gut

Li J, Liang X, Jiang J, Yang L, Xin J, Shi D, Lu Y, Li J, Ren K, Hassan HM, Zhang J, Chen P, Yao H, Li J, Wu T, Jin L, Ye P, Li T, Zhang H, Sun S, Guo B, Zhou X, Cai Q, Chen J, Xu X, Huang J, Hao S, He J, Xin S, Wang D, Trebicka J, Chen X, Li J.
PMID: 33431576
Gut. 2022 Jan;71(1):163-175. doi: 10.1136/gutjnl-2020-323395. Epub 2021 Jan 11.

OBJECTIVE: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) pathophysiology remains unclear. This study aims to characterise the molecular basis of HBV-ACLF using transcriptomics.METHODS: Four hundred subjects with HBV-ACLF, acute-on-chronic hepatic dysfunction (ACHD), liver cirrhosis (LC) or chronic hepatitis B...

Cite
Li J, Liang X, Jiang J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF. Gut. 2021;71(1):163-175doi: 10.1136/gutjnl-2020-323395.
Li, J., Liang, X., Jiang, J., Yang, L., Xin, J., Shi, D., Lu, Y., Li, J., Ren, K., Hassan, H. M., Zhang, J., Chen, P., Yao, H., Li, J., Wu, T., Jin, L., Ye, P., Li, T., Zhang, H., Sun, S., Guo, B., Zhou, X., Cai, Q., Chen, J., Xu, X., Huang, J., Hao, S., He, J., Xin, S., Wang, D., Trebicka, J., Chen, X., Li, J. (2022). PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF. Gut, 71(1), 163-175. https://doi.org/10.1136/gutjnl-2020-323395
Li, Jiang, et al. "PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF." Gut vol. 71,1 (2022): 163-175. doi: https://doi.org/10.1136/gutjnl-2020-323395
Li J, Liang X, Jiang J, Yang L, Xin J, Shi D, Lu Y, Li J, Ren K, Hassan HM, Zhang J, Chen P, Yao H, Li J, Wu T, Jin L, Ye P, Li T, Zhang H, Sun S, Guo B, Zhou X, Cai Q, Chen J, Xu X, Huang J, Hao S, He J, Xin S, Wang D, Trebicka J, Chen X, Li J. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF. Gut. 2022 Jan;71(1):163-175. doi: 10.1136/gutjnl-2020-323395. Epub 2021 Jan 11. PMID: 33431576; PMCID: PMC8666828.
Copy Download .nbib Format: NLM
The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis.

Hepatology communications

Innes H, Nischalke HD, Guha IN, Weiss KH, Irving W, Gotthardt D, Barnes E, Fischer J, Ansari MA, Rosendahl J, Lin SK, Marot A, Pedergnana V, Casper M, Benselin J, Lammert F, McLauchlan J, Lutz PL, Hamill V, Mueller S, Morling JR, Semmler G, Eyer F, von Felden J, Link A, Vogel A, Marquardt JU, Sulk S, Trebicka J, Valenti L, Datz C, Reiberger T, Schafmayer C, Berg T, Deltenre P, Hampe J, Stickel F, Buch S.
PMID: 34958182
Hepatol Commun. 2021 Dec 27; doi: 10.1002/hep4.1886. Epub 2021 Dec 27.

The host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing component 1 (MARC1), rs2792751 in glycerol-3-phosphate acyltransferase (GPAM), and...

Cite
Innes H, Nischalke HD, Guha IN, et al. The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatol Commun. 2021;doi: 10.1002/hep4.1886.
Innes, H., Nischalke, H. D., Guha, I. N., Weiss, K. H., Irving, W., Gotthardt, D., Barnes, E., Fischer, J., Ansari, M. A., Rosendahl, J., Lin, S. K., Marot, A., Pedergnana, V., Casper, M., Benselin, J., Lammert, F., McLauchlan, J., Lutz, P. L., Hamill, V., Mueller, S., Morling, J. R., Semmler, G., Eyer, F., von Felden, J., Link, A., Vogel, A., Marquardt, J. U., Sulk, S., Trebicka, J., Valenti, L., Datz, C., Reiberger, T., Schafmayer, C., Berg, T., Deltenre, P., Hampe, J., Stickel, F., & Buch, S. (2021). The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology communications, . https://doi.org/10.1002/hep4.1886
Innes, Hamish, et al. "The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis." Hepatology communications vol. (2021). doi: https://doi.org/10.1002/hep4.1886
Innes H, Nischalke HD, Guha IN, Weiss KH, Irving W, Gotthardt D, Barnes E, Fischer J, Ansari MA, Rosendahl J, Lin SK, Marot A, Pedergnana V, Casper M, Benselin J, Lammert F, McLauchlan J, Lutz PL, Hamill V, Mueller S, Morling JR, Semmler G, Eyer F, von Felden J, Link A, Vogel A, Marquardt JU, Sulk S, Trebicka J, Valenti L, Datz C, Reiberger T, Schafmayer C, Berg T, Deltenre P, Hampe J, Stickel F, Buch S. The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatol Commun. 2021 Dec 27; doi: 10.1002/hep4.1886. Epub 2021 Dec 27. PMID: 34958182.
Copy Download .nbib Format: NLM
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium.

Journal of hepatology

Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P.
PMID: 32896580
J Hepatol. 2021 Jan;74(1):200-219. doi: 10.1016/j.jhep.2020.08.009. Epub 2020 Sep 05.

Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with...

Cite
Solà E, Pose E, Campion D, et al. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol. 2020;74(1):200-219doi: 10.1016/j.jhep.2020.08.009.
Solà, E., Pose, E., Campion, D., Piano, S., Roux, O., Simon-Talero, M., Uschner, F., de Wit, K., Zaccherini, G., Alessandria, C., Beuers, U., Caraceni, P., Francoz, C., Mookerjee, R. P., Trebicka, J., Vargas, V., Serra, M., Torres, F., Montagnese, S., Krag, A., Hernaez, R., Korenjak, M., Watson, H., Abraldes, J. G., Kamath, P. S., Ginès, P. (2021). Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. Journal of hepatology, 74(1), 200-219. https://doi.org/10.1016/j.jhep.2020.08.009
Solà, Elsa, et al. "Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium." Journal of hepatology vol. 74,1 (2021): 200-219. doi: https://doi.org/10.1016/j.jhep.2020.08.009
Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol. 2021 Jan;74(1):200-219. doi: 10.1016/j.jhep.2020.08.009. Epub 2020 Sep 05. PMID: 32896580.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 145 entries